The article cited AMA's "Global Healthcare Regulatory Affairs Outsourcing Market Study" explored CAGR of %. According to the report, Increased Demand of Skilled and Trained Regulatory Professionals is one of the prima...
AdvanceMarketAnalytics, a global market research and consulting organization, have released a new study titled "Medical Micro Injection Molding market - Global outlook to 2025". Industries constant focus on reducing the...
A new research document titled, “Global Dental Block Market” is released by AdvanceMarketAnalytics. The market study is a cautious attempt of the industry with strategic steps to the targets of business environ...
According to the report, High Demand for Advanced Treatment Options for Chronic Diseases is one of the primary growth factors for the market. Increased Prevalence of Gastrointestinal Diseases
is also expected to cont...
The revenue mix of most of the companies of Interstitial Lung Disease Treatment Market may change in coming time. One of the important factors would be the shift in topline of the clientele that will push them hard to ad...
The article cited AMA's "Global Cardiac Arrest Treatment Market Study" explored CAGR of %. According to the report, Increasing Number of Research Activities is one of the primary growth factors for the market. Rise in...
In April 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for blood purification equipment to treat COVID-19 positive patients. The article cited AMA's "Global Blood Purification D...
In Jan 2021, the U.S. Food and Drug Administration conditionally approved Laverdia-CA1 (verdinexor tablets) to treat dogs with lymphoma, a type of cancer of the lymph nodes and lymphatic system. Laverdia-CA1 works to pre...
Market Highlights: Wound tissue analysis solutions are designed for tissue analysis of wounds to determine characterization and classification of wounds so as to determine the prognosis for optimum rate and degree of hea...
The US Food and Drug Administration had approved Trikafta (elexacaftor / ivacaftor / tezacaftor), which is the first triple combination therapy that is available for the treatment of patients with cystic fibrosis mutatio...
